Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Corporate Authors:
      ReaL (NN2211-4118) Study Group*
    • Source:
      Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9200299 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-5233 (Electronic) Linking ISSN: 09405429 NLM ISO Abbreviation: Acta Diabetol Subsets: MEDLINE
    • Publication Information:
      Publication: Berlin : Springer Verlag
      Original Publication: Berlin : Springer International, c1991-
    • Subject Terms:
      Biomarkers/*analysis ; Diabetes Mellitus, Type 2/*drug therapy ; Hypoglycemic Agents/*therapeutic use ; Liraglutide/*therapeutic use; Aged ; Blood Glucose/analysis ; Databases, Factual ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/epidemiology ; Electronic Health Records/statistics & numerical data ; Female ; Glycated Hemoglobin/analysis ; Humans ; Italy/epidemiology ; Longitudinal Studies ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Treatment Outcome ; Weight Loss/drug effects
    • Abstract:
      Aims: There is an unmet need among healthcare providers to identify subgroups of patients with type 2 diabetes who are most likely to respond to treatment.
      Methods: Data were taken from electronic medical records of participants of an observational, retrospective study in Italy. We used logistic regression models to assess the odds of achieving glycated haemoglobin (HbA 1c ) reduction ≥ 1.0% point after 12-month treatment with liraglutide (primary endpoint), according to various patient-related factors. RECursive Partitioning and AMalgamation (RECPAM) analysis was used to identify distinct homogeneous patient subgroups with different odds of achieving the primary endpoint.
      Results: Data from 1325 patients were included, of which 577 (43.5%) achieved HbA 1c reduction ≥ 1.0% point (10.9 mmol/mol) after 12 months. Logistic regression showed that for each additional 1% HbA 1c at baseline, the odds of reaching this endpoint were increased 3.5 times (95% CI: 2.90-4.32). By use of RECPAM analysis, five distinct responder subgroups were identified, with baseline HbA 1c and diabetes duration as the two splitting variables. Patients in the most poorly controlled subgroup (RECPAM Class 1, mean baseline HbA 1c  > 9.1% [76 mmol/mol]) had a 28-fold higher odds of reaching the endpoint versus patients in the best-controlled group (mean baseline HbA 1c  ≤ 7.5% [58 mmol/mol]). Mean HbA 1c reduction from baseline was as large as - 2.2% (24 mol/mol) in the former versus - 0.1% (1.1 mmol/mol) in the latter. Mean weight reduction ranged from 2.5 to 4.3 kg across RECPAM subgroups.
      Conclusions: Glycaemic response to liraglutide is largely driven by baseline HbA 1c levels and, to a lesser extent, by diabetes duration.
    • References:
      J Diabetes Investig. 2012 Jun 6;3(3):294-7. (PMID: 24843579)
      Lancet. 2009 Feb 7;373(9662):473-81. (PMID: 18819705)
      Diabetologia. 2009 Oct;52(10):2046-55. (PMID: 19688338)
      Adv Ther. 2018 Feb;35(2):243-253. (PMID: 29270781)
      Diabetes Ther. 2016 Sep;7(3):411-38. (PMID: 27350545)
      Diabetol Metab Syndr. 2014 Sep 08;6(1):95. (PMID: 25237400)
      Diabetes Care. 2009 Jan;32(1):84-90. (PMID: 18931095)
      Nephrol Dial Transplant. 2008 Apr;23(4):1278-84. (PMID: 18039647)
      Clin Ther. 2015 Mar 1;37(3):574-84. (PMID: 25626486)
      Diabet Med. 2009 Mar;26(3):268-78. (PMID: 19317822)
      Nutr Metab Cardiovasc Dis. 2010 Jan;20(1):7-14. (PMID: 19747804)
      Clin Ther. 2017 Jan;39(1):159-169. (PMID: 27939305)
      Diabet Med. 2010 Mar;27(3):309-17. (PMID: 20536494)
      Acta Diabetol. 2017 Feb;54(2):123-131. (PMID: 27718051)
      Minerva Endocrinol. 2016 Mar;41(1):35-42. (PMID: 26878560)
      J Diabetes Complications. 2013 Jan-Feb;27(1):87-91. (PMID: 22863615)
      Adv Ther. 2015 Sep;32(9):838-53. (PMID: 26424330)
      Diabetes Care. 2017 Jan;40(Suppl 1):S1-S2. (PMID: 27979885)
      Lancet. 2009 Jul 4;374(9683):39-47. (PMID: 19515413)
      N Engl J Med. 2016 Jul 28;375(4):311-22. (PMID: 27295427)
      Diabetes Care. 2009 Jul;32(7):1224-30. (PMID: 19289857)
      Diabetes Res Clin Pract. 2014 Dec;106(3):451-7. (PMID: 25458335)
    • Contributed Indexing:
      Investigator: N Simioni; C Berra; M Boemi; AC Bossi; R Candido; G Di Cianni; S Frontoni; S Genovese; P Ponzani; V Provenzano; G Russo; L Sciangula; A Lapolla; C Bette; MC Rossi
      Keywords: GLP-1RA; Liraglutide; RECPAM analysis; Response to therapy; Type 2 diabetes
    • Accession Number:
      0 (Biomarkers)
      0 (Blood Glucose)
      0 (Glycated Hemoglobin A)
      0 (Hypoglycemic Agents)
      839I73S42A (Liraglutide)
    • Publication Date:
      Date Created: 20180313 Date Completed: 20180717 Latest Revision: 20240325
    • Publication Date:
      20240325
    • Accession Number:
      PMC5959971
    • Accession Number:
      10.1007/s00592-018-1124-0
    • Accession Number:
      29527621